Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03126630 · OUTCOME

Phase 2 Overall Survival

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma · Source last updated 2026-04-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From the start of treatment to death due to any cause, assessed up to 2 years

What was measured

Will be estimated using the method of Kaplan-Meier. The comparison of overall survival in event of death between two treatment arms will be based on the log-rank test.

Groups in this outcome

Group I (Pembrolizumab)

Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Upon radiologic documentation of disease progression, patients may cross over to Group II.\> \>\> \> \>\> Laboratory Biomarker Analysis: Correlative studies\> \>\> \> \>\> Pembrolizumab: Given IV\> \>\> \> \>\> Pharmacological Study: Correlative studies

Group II (Anetumab Ravtansine, Pembrolizumab)

Patients receive anetumab ravtansine IV over 1 hour and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 12 months for anetumab ravtansine and up to 24 months for pembrolizumab in the absence of disease progression or unacceptable toxicity.\> \>\> \> \>\> Anetumab Ravtansine: Given IV\> \>\> \> \>\> Laboratory Biomarker Analysis: Correlative studies\> \>\> \> \>\> Pembrolizumab: Given IV\> \>\> \> \>\> Pharmacological Study: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Group I (Pembrolizumab)17
Group II (Anetumab Ravtansine, Pembrolizumab)18

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Group I (Pembrolizumab)0Not reportedNot reportedNot reportedNot reported
Group II (Anetumab Ravtansine, Pembrolizumab)2Not reportedNot reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    0.0
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit Comment
    Not enough events
    group Ids
    1. OG000
    non Inferiority Type
    SUPERIORITY
    p Value
    0.1936
    param Type
    Hazard Ratio (HR)
    param Value
    0.0
    statistical Method
    Log Rank
Complete source fields
analyses
  1. ci Lower Limit
    0.0
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit Comment
    Not enough events
    group Ids
    1. OG000
    non Inferiority Type
    SUPERIORITY
    p Value
    0.1936
    param Type
    Hazard Ratio (HR)
    param Value
    0.0
    statistical Method
    Log Rank
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        2
denoms
  1. counts
    1. group Id
      OG000
      value
      17
    2. group Id
      OG001
      value
      18
    units
    Participants
description
Will be estimated using the method of Kaplan-Meier. The comparison of overall survival in event of death between two treatment arms will be based on the log-rank test.
groups
  1. description
    Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Upon radiologic documentation of disease progression, patients may cross over to Group II.\> \>\> \> \>\> Laboratory Biomarker Analysis: Correlative studies\> \>\> \> \>\> Pembrolizumab: Given IV\> \>\> \> \>\> Pharmacological Study: Correlative studies
    id
    OG000
    title
    Group I (Pembrolizumab)
  2. description
    Patients receive anetumab ravtansine IV over 1 hour and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 12 months for anetumab ravtansine and up to 24 months for pembrolizumab in the absence of disease progression or unacceptable toxicity.\> \>\> \> \>\> Anetumab Ravtansine: Given IV\> \>\> \> \>\> Laboratory Biomarker Analysis: Correlative studies\> \>\> \> \>\> Pembrolizumab: Given IV\> \>\> \> \>\> Pharmacological Study: Correlative studies
    id
    OG001
    title
    Group II (Anetumab Ravtansine, Pembrolizumab)
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
From the start of treatment to death due to any cause, assessed up to 2 years
title
Phase 2 Overall Survival
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice